Original Research
Accepted on 30 Dec 2025
Structure-guided design of a bivalent SARS-CoV-2 mRNA vaccine with NTD stabilizing mutations enhances broad immunity
in Vaccines and Molecular Therapeutics
- 178 views
Original Research
Accepted on 30 Dec 2025
in Vaccines and Molecular Therapeutics
Original Research
Accepted on 30 Dec 2025
in Vaccines and Molecular Therapeutics
Review
Accepted on 29 Dec 2025
in Vaccines and Molecular Therapeutics
Original Research
Accepted on 29 Dec 2025
in Vaccines and Molecular Therapeutics
Original Research
Accepted on 26 Dec 2025
in Vaccines and Molecular Therapeutics
Review
Accepted on 24 Dec 2025
in Vaccines and Molecular Therapeutics
Review
Accepted on 23 Dec 2025
in Vaccines and Molecular Therapeutics
Editorial
Accepted on 23 Dec 2025
in Vaccines and Molecular Therapeutics
Original Research
Accepted on 22 Dec 2025
in Vaccines and Molecular Therapeutics
Original Research
Accepted on 22 Dec 2025
in Vaccines and Molecular Therapeutics
Review
Accepted on 19 Dec 2025
in Vaccines and Molecular Therapeutics
Systematic Review
Accepted on 19 Dec 2025
in Vaccines and Molecular Therapeutics
Original Research
Accepted on 19 Dec 2025
in Vaccines and Molecular Therapeutics
Original Research
Accepted on 18 Dec 2025
in Vaccines and Molecular Therapeutics
Original Research
Accepted on 18 Dec 2025
in Vaccines and Molecular Therapeutics
Original Research
Published on 18 Dec 2025
in Vaccines and Molecular Therapeutics
Review
Accepted on 17 Dec 2025
in Vaccines and Molecular Therapeutics
Original Research
Published on 17 Dec 2025
in Vaccines and Molecular Therapeutics
Original Research
Published on 17 Dec 2025
in Vaccines and Molecular Therapeutics
Original Research
Published on 17 Dec 2025
in Vaccines and Molecular Therapeutics
Perspective
Published on 16 Dec 2025
in Vaccines and Molecular Therapeutics
Original Research
Accepted on 15 Dec 2025
in Vaccines and Molecular Therapeutics
Original Research
Accepted on 15 Dec 2025
in Vaccines and Molecular Therapeutics
Original Research
Accepted on 15 Dec 2025
in Vaccines and Molecular Therapeutics